Fortress Biotech Cultura de la Empresa

Dr. Lindsay Allan Rosenwald, M.D., serves as the Chairman of the Board of Directors at Avenue Therapeutics, Inc since February, 2015. He has been Chairman, Chief Executive Officer and President of Fortress Biotech, Inc. (formerly known as Coronado Biosciences, Inc.) since December 19, 2013. Dr. Rosenwald has been a member of the Board of Directors of Fortress since October 2009. Over the 23 years, Dr. Rosenwald has acted as a biotechnology entrepreneur and has been involved in the founding and recapitalization of numerous public and private biotechnology and life sciences companies. Dr. Rosenwald has experience in creating, financing and investing in biotechnology and life-sciences companies and has been an investment banker, venture capitalist and fund manager. Dr. Rosenwald served as the Co-Chairman and Chief Executive Officer of Origo Acquisition Corporation (alternative name CB Pharma Acquisition Corp.) from August 26, 2014 to June 10, 2016. Dr. Rosenwald joined CB Pharma Acquisition Corp in 2014. Dr. Rosenwald is the Founder of Paramount BioSciences, LLC. and serves as its Chairman and Chief Executive Officer. Dr. Rosenwald is the Founder of Paramount Capital Inc. and serves as its Chief Executive Officer and Chairman. Dr. Rosenwald is the Founder of Interneuron Pharmaceuticals Inc. and serves as its Chairman. He is the General Partner at Aries Domestic Fund LP. He is the Founder of Greenwich Therapeutics, Inc. Dr. Rosenwald is the Founder of Paramount BioCapital Asset Management, Inc. He is founder of Paramount BioCapital, Inc. He served as President and Chief Executive Officer of Checkpoint Therapeutics, Inc from November 2014 to August 2015. Dr. Rosenwald serves as Co-Portfolio Manager and Partner of Opus Point Partners Management, LLC (???Opus Point???), an asset management firm in the life sciences industry, which he co-founded in 2009. Over the 23 years, Dr. Rosenwald acted as a biotechnology entrepreneur and has been involved in the founding and recapitalization of numerous public and private biotechnology and life sciences companies. Dr. Rosenwald has been Chief Executive Officer at Paramount BioCapital, Inc. since 1991. Dr. Rosenwald served as Chief Executive Officer and Chairman at Paramount BioCapital Asset Management, Inc. from 1994 to 2008. He served as Chief Executive Officer and President of Avenue Therapeutics, Inc. from November 2014 to August 2015 and has been its Executive Chairman since February 2015. He serves as Executive Chairman of the Board at Helocyte Inc. From 1991 to 2008, he served as the Chairman of Paramount BioCapital, Inc. He also served as managing member of Paramount Biosciences LLC (and its predecessor, Paramount BioCapital Investments, LLC), an entity engaged in the research, formation and acquisition of seed-stage and distressed life science technologies and companies, identifying and evaluating a broad spectrum of therapeutic and medical technologies in order to capture innovations with significant commercial potential from 1996 to 2008. He also has biotechnology and pharmaceutical industry experience and in-depth understanding of business. He co-founded Endo Pharmaceuticals Solutions Inc. (formerly Indevus Pharmaceuticals Inc.). He was employed at Neose Technologies, Inc. He served as the Founder, Chief Executive Officer and Chairman at Paramount Capital Investments, L.L.C. He founded numerous biopharmaceutical companies and serves as an Officer or Director at several privately held biopharmaceutical companies. Dr. Rosenwald served as the Chairman at Indevus Pharmaceuticals from February 1989 to January 19, 2000. He serves as Chairman of the Board of Paramount Capital Asset Management, Inc. Dr. Rosenwald served as Chairman of the Board of Paramount Acquisition Corp. since October 2005 until its merger with B.J.K. Inc. in October 2007. He served as Chairman of Chem Rx Corporation since June 1, 2005. He serves as a Director at Helocyte Inc. He has been Non Executive Director of Mustang Bio Inc. since March 13, 2015. He serves as a Member of the Board of Directors of, Avigen Inc.; BioCryst Pharmaceuticals Inc.; Titan Pharmaceuticals Inc.; VimRx Pharmaceuticals Inc.; Neose Technologies Inc. and Access Oncology. He has been a Non-Executive Director of Checkpoint Therapeutics, Inc. since November 10, 2014. Dr. Rosenwald has been a Director of Fortress Biotech, Inc. since October 2009. Dr. Rosenwald has been a Director of Coronado BioSciences, Inc. since October 2009. He served as a Director of Keryx Biopharmaceuticals Inc., since March 2000 until November 2006. He served as a Director of Endo Pharmaceuticals Solutions Inc. He served as a Director of Cougar Biotechnology, Inc. since May 2003 until July 18, 2007. He served as a Director of Chem Rx Corporation since June 1, 2005 until January 2008. Prior thereto, he served as a Member of the Board of Directors of Indevus Pharmaceuticals Inc., until August 29, 2003 and Sparta Pharmaceuticals since February 1991. Dr. Rosenwald received a B.S. in Finance from Pennsylvania State University and an M.D. from Temple University School of Medicine.

Dr. George C. Avgerinos, Ph.D., serves as Chief Operating Officer and Secretary at Fortress Biotech, Inc. (formerly known as Coronado Biosciences, Inc.) and has been its Senior Vice President of Biologics Operations since June 4, 2013. Dr. Avgerinos served as the Chief Operating Officer and Secretary at CB Pharma Acquisition Corp. from August 26, 2014 to June 10, 2016. He was at AbbVie, where he served as Vice President of HUMIRA(R) Manufacturing Sciences and External Partnerships. In his 23 year career at AbbVie, (formerly Abbott Laboratories, formerly BASF Bioresearch Corporation), he had responsibility for many aspects of Biologics development and operations. These included the HUMIRA(R) operations franchise, global biologics process and manufacturing sciences, biologics CMC, manufacturing operations and third party manufacturing. During his tenure, Dr. Avgerinos led and participated in the development of numerous clinical candidates which included the launch of HUMIRA(R). Dr. Avgerinos started his career at Biogen, Inc. in 1981 and subsequently joined Collaborative Research Inc. while serving as an Adjunct Associate Professor of Chemical Engineering at Tufts University. He supported expansion of the supply chain to over $9 Billion in annual global sales in its enviable position as the world's largest selling drug. His efforts on HUMIRA(R) have been recognized with numerous awards, including the prestigious Abbott's Chairman's award in 2011. He has authored numerous publications in the area of biotechnology product development and manufacturing and holds a number of product and process patents. Dr. Avgerinos received a B.A. in Biophysics from the University of Connecticut and a Ph.D. in Biochemical Engineering from the Massachusetts Institute of Technology.

Ms. Robyn M. Hunter has been the Chief Financial Officer at Fortress Biotech, Inc. since June 26, 2017. Ms. Hunter serves as Corporate Secretary of Mustang Bio Inc. She served as the Chief Financial Officer and Senior Vice President of Finance & Compliance at Schochet Associates, Inc./Federal Management Co Inc. from January 2006 to 2011. She served as Corporate Controller at Indevus Pharmaceuticals from 2004 to 2006. She served as the Chief Financial Officer and Vice President at Stackpole Corporation from 1991 to 2004. She served as an Accounting Operations Supervisor at Xyvision Inc. She served as Staff Accountant at Automatix Inc. She served as an Audit Staff Assistant at PwC. She served as Vice President and Corporate Controller at Fortress Biotech Inc since August 2011. Prior to Schochet Associates, Ms. Hunter held senior financial positions in the manufacturing and bio pharmaceuticals industries. Ms. Hunter holds a Bachelor in Economics from Union College in Schenectady New York from 1979 to 1983.

Dr. Lucy Lu, M.D., has been a Director of Veru Inc since October 31, 2016. Dr. Lu has served as Executive Vice President and Chief Financial Officer of Coronado Biosciences Inc. since February 2012. She was a Senior Biotechnology Equity Analyst at Citi Investment Research since February 2007. Prior to Citigroup, Dr. Lu was a Senior Analyst at First Albany Capital as a Vice President and Principal from April 2004 to February 2007. She started her career at Lehman Brothers as an Associate of Healthcare Investment Banking. Dr. Lu holds an M.D. degree from the New York University School of Medicine and an M.B.A. from the Leonard N. Stern School of Business at New York University. Dr. Lu obtained a B.A. from the University of Tennessee's College of Arts and Science.

Mr. Timothy M. Hillman has been Vice President of Operations at fortress Biotech, Inc since June 2010. Mr. Hillman has over 15 years of Pharmaceutical/Biotechnology experience. He served as Senior Director, Business Development and Strategic Planning at Gentium S.p.A and held Senior level business development, sales & marketing & finance positions at Mylan Inc., Mayne Pharma, and Johnson & Johnson. He received B.S. in Biochemistry from the University of Texas at Austin, M.Sc. in Biochemistry & Cell Biology from Rice University and M.B.A. in Finance from Cornell University, Johnson Graduate School of Management.

Arthur Ross serves as the VP of Business Development for Fortress Biotech. Arthur started at Fortress Biotech in July of 2015. Arthur is based in the Greater New York City Area.

Valerie Jaiswal serves as the VP, Financial Planning & Analysis for Fortress Biotech. Valerie started at Fortress Biotech in February of 2018. Valerie is based in the Greater New York City Area.

Keren Paz serves as the SVP Scientific & Medical Research for Fortress Biotech. Keren started at Fortress Biotech in December of 2016. Keren is based in the Greater New York City Area.

Leonid Gorelik serves as the Vice President of Drug Discovery of Fortress Biotech. Leonid currently resides in the Greater Boston Area.